Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

284
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
284
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.4K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.4K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

278
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
278
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

194
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
194
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

255
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
255
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

286
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
286

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of the somatic landscape and transcriptional profile of breast tumors from 748 Hispanic/Latina women in California.

medRxiv : the preprint server for health sciences·2026
Same author

Transferrin confers imidacloprid resistance by attenuating ROS-induced apoptotic signaling in the white-backed planthopper, Sogatella furcifera.

Pesticide biochemistry and physiology·2026
Same author

Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and stabilizing BAG3.

Cell death and differentiation·2026
Same author

Bayesian reinforcement learning for adaptive control of energy recuperation in hydraulic excavator arms.

Scientific reports·2026
Same author

Walnut peptide and theanine combination ameliorates sleep disorders: a multi-species study including a human trial.

Food & function·2026
Same author

Pulmonary immunohistochemical markers may be positive in gastric adenocarcinomas associated with autoimmune metaplastic atrophic gastritis.

Histopathology·2026

Related Experiment Video

Updated: Feb 17, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.6K

A single institution experience with palbociclib toxicity requiring dose modifications.

Jun Gong1, May Cho1, Kim Wai Yu1

  • 1Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E Duarte Rd, Duarte, CA, 91010, USA.

Breast Cancer Research and Treatment
|December 9, 2017
PubMed
Summary

Palbociclib dose modifications for myelosuppression, primarily neutropenia, are common in breast cancer treatment. Most dose adjustments occur early, with reduction to 100 mg being the preferred method.

Keywords:
Breast cancerDose modificationHormone receptor positiveNeutropeniaPalbociclibPostmenopausal

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
10:38

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

2.8K

Related Experiment Videos

Last Updated: Feb 17, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.6K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
10:38

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

2.8K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Palbociclib combined with endocrine therapy is a standard treatment for advanced HR+, HER2- breast cancer.
  • Myelosuppression is a recognized toxicity of palbociclib, often necessitating dose modifications.

Purpose of the Study:

  • To characterize toxicities leading to palbociclib dose modifications outside of clinical trials.
  • To understand prescriber preferences for palbociclib dose adjustments.

Main Methods:

  • Retrospective study of patients with advanced HR+, HER2- breast cancer receiving palbociclib and endocrine therapy.
  • Analysis of adverse events, dose modifications, and prescriber-chosen modification methods.

Main Results:

  • 38% of patients required palbociclib dose modifications due to adverse events; 18.4% required subsequent changes.
  • Grade 3-4 neutropenia was the most frequent cause (54.8%) of dose modification.
  • Dose reduction from 125 mg to 100 mg was the most common prescriber preference (65.8%).
  • Older patients (≥65) showed similar tolerance and modification rates, with neutropenia being the primary driver.

Conclusions:

  • Neutropenia is the main reason for palbociclib dose modification, typically within the first two cycles.
  • Age ≥65 did not impact palbociclib tolerance or the need for dose adjustments.
  • Findings offer real-world insights into palbociclib safety and management in breast cancer therapy.